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Abstract
This investigation examined how the nutritional status of rats fed a
low-protein diet was affected when the animals were treated with the
ß-2 selective agonist clenbuterol (CL). Males (4 weeks old) from an
inbred, specific-pathogen-free strain of hooded rats maintained at the
Dunn Nutritional Laboratory were used in the experiments (N = 6 rats
per group). CL treatment (Ventipulmin, Boehringer-Ingelheim Ltd.,
3.2 mg/kg diet for 2 weeks) caused an exacerbation of the symptoms
associated with protein deficiency in rats. Plasma albumin concentra-
tions, already low in rats fed a low-protein diet (group A), were further
reduced in CL rats (A = 25.05 ± 0.31 vs CL = 23.64 ± 0.30 g/l, P<0.05).
Total liver protein decreased below the level seen in either pair-fed
animals (group P) or animals with free access to the low-protein diet
(A = 736.56 ± 26 vs CL = 535.41 ± 54 mg, P<0.05), whereas
gastrocnemius muscle protein was higher than the values normally
described for control (C) animals (C = 210.88 ± 3.2 vs CL = 227.14 ±
1.7 mg/g, P<0.05). Clenbuterol-treated rats also showed a reduction in
growth when compared to P rats (P = 3.2 ± 1.1 vs CL = -10.2 ± 1.9 g,
P<0.05). This was associated with a marked decrease in fat stores (P =
5.35 ± 0.81 vs CL = 2.02 ± 0.16 g, P<0.05). Brown adipose tissue
(BAT) cytochrome oxidase activity, although slightly lower than in P
rats (P = 469.96 ± 16.20 vs CL = 414.48 ± 11.32 U/BAT x kg body
weight, P<0.05), was still much higher than in control rats (C = 159.55
± 11.54 vs CL = 414.48 ± 11.32 U/BAT x kg body weight, P<0.05).
The present findings support the hypothesis that an increased muscle
protein content due to clenbuterol stimulation worsened amino acid
availability to the liver and further reduced albumin synthesis causing
exacerbation of hypoalbuminemia in rats fed a low-protein diet.
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Introduction
Hypoalbuminemia is a primary feature of
the protein-energy malnutrition syndrome
kwashiorkor. Data from balance studies have
shown that for hypoalbuminemia to occur,
not only has dietary protein to be inadequate,
but it is also necessary for energy consump-
tion to be in excess of requirements for the
protein-limited growth rate (1,2). However,
the mechanisms by which an energy surplus
interferes with protein metabolism remain
unknown.
It is now well established that rats and
other animals fed diets of low protein con-
tent become hyperphagic, but are able to
dissipate much of their energy surfeit by a
rise in diet-induced thermogenesis (3). In
particular, a large increase in the activity of
brown adipose tissue has been described (4-
6). In keeping with this picture, one of the
hormones most directly involved in energy
dissipation, norepinephrine (NE), is elevated
in rats fed low-protein diets (7,8). Many
studies (9-13) have also demonstrated an
increased protein deposition and an eleva-
tion in the rate of protein synthesis in skel-
etal muscle when either normal rats or rats
fed a low-protein diet were treated with the
specific ß-2 selective agonist, clenbuterol. It
is therefore possible that the increase in nor-
epinephrine levels which occurs as a meta-
bolic consequence of excess energy intake
might act to maintain skeletal muscle protein
even when dietary protein intake is limited.
Clearly, such a mechanism could explain the
inappropriate protein distribution and hy-
poalbuminemia seen in protein-deficient rats
(14,15) and the ‘dysadaptation’ syndrome of
kwashiorkor in children (16,17).
Although studies of the effects of ß-adre-
nergic agonists on metabolic rate and brown
adipose tissue (BAT) activity have indicated
that the actions of the sympathetic nervous
system on BAT are mediated predominantly
by ß-1-type adrenoceptors, ß-2 selective ad-
renergic agonists are also involved since a
total inhibition can only be achieved by a
combination of ß-1 and ß-2 receptor antago-
nists (18). In fact, like ß-1 drugs, ß-2 selec-
tive adrenergic agonists stimulate oxygen
consumption in rats, and raise both BAT
temperature and the activity of the mito-
chondrial proton-conductance pathway in
this tissue (9).
The present report describes an attempt
to produce metabolic changes which stimu-
late muscle protein synthesis and energy
dissipation in rats fed diets of low protein
content, by administration of the ß-2 selec-
tive agonist clenbuterol. We expected that an
increase in sympathetic activity would
worsen the features previously reported for
rats fed low-protein diets (6), and therefore
cause a greater reduction in plasma albumin.
This could be reasonable evidence that hy-
poalbuminemia is also promoted by increased
ß-2 selective agonist activity during con-
sumption of low-protein diets. In addition, to
have a better picture of the metabolic changes
produced by the present drug treatment, two
hormones, T3 and insulin, known to be asso-
ciated with plasma albumin levels in rats fed
a low-protein diet, were measured (1,4,6,15).
Material and Methods
Males from an inbred, specific-patho-
gen-free strain of hooded rats maintained at
the Dunn Nutritional Laboratory were used
in the experiments. Animals were weaned at
3 weeks to a synthetic casein-based diet of
protein energy:total energy (P:E) ratio 0.20
(Table 1) for 1 week before the experimental
procedures began and then divided into 3
groups. Rats in the control group (A) were
given free access to a low-protein diet (P:E
0.03) for 2 weeks (Table 1). In the drug-
treated rats (group CL), clenbuterol hydro-
chloride (a specific ß-2 selective agonist,
market as Ventipulmin, Boehringer-Ingel-
heim Ltd., London, UK) was mixed into the
low-protein diet (3.2 mg/kg diet) for 2 weeks.
A third group, receiving the control low-
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protein diet, was pair-fed with CL animals
(group P).
During the experimental period the rats
were individually housed in wire cages fitted
with trays to collect food spillage. Ambient
temperature was kept at 20-23oC and a 12-h
light-dark cycle was maintained. Food and
water were freely available. Animals were
weighed and their food consumption was
recorded daily.
At the end of the experimental period, the
animals were killed between 10:00 and 11:00
h by exsanguination under diethyl ether an-
esthesia. Blood was collected into heparin-
ized tubes and the resulting plasma stored at
-20oC until required for analysis. Interscapu-
lar BAT was removed into ice cold SHE
buffer (0.25 mol/l sucrose, 0.1 mmol/l
HEPES, 0.1 mol/l dipotassium EDTA, pH
7.2) and separated from adhering muscle
and white fat. It was then blotted, weighed
and homogenized and kept at 4oC for the
assay of cytochrome oxidase activity. The
liver and the gastrocnemius muscle from one
leg were removed and weighed, and aliquots
taken into small tin capsules for nitrogen
analysis using an automated nitrogen ana-
lyzer (Dumas Analyzer, Carlo Erba, Erba
Science, Swindon, UK). Protein was calcu-
lated as N x 6.25.
Assays
Cytochrome c oxidase (EC 1.9.3.1.) was
assayed in BAT homogenates by following
the oxidation of reduced cytochrome c spec-
trophotometrically at 550 nm according to
the method of Yonetani and Ray (19). Plasma
albumin was determined using a bromocre-
sol green technique (6). Concentrations of
T3 and insulin in plasma were measured by
radioimmunoassay using reagents supplied
in kit form by Amersham International
(Amersham, Bucks, UK).
An estimate of the carcass composition
was obtained by freeze drying the animal
carcass. Body water (%) and body fat (%)
were calculated from total body water con-
tent measured by desiccation. It was assumed
that water constituted 732 g/kg of the fat-free
wet weight of the animals (20) according to
the equation: % fat = 100 (1 - % total body
water)/0.732. Then the percentage of fat was
converted to total body fat by the equation:
% fat x body weight/100.
Statistical differences were assessed us-
ing one-way ANOVA. Fisher’s least-signifi-
cant-difference test was performed subse-
quently for pair comparisons.
Results
No differences in food consumption were
observed between the groups studied (Table
2). In spite of this, a marked reduction in
weight gain was observed when rats with
free access to the low-protein diet (group A)
were compared to normally fed controls
(group C) (Table 2). Administration of
clenbuterol to rats fed a low-protein diet
reduced body weight when the results were
compared with either pair-fed (group P) or
Table 1 - Composition of the control and low-protein diets given to rats.
*Containing 250 g/kg calcium carbonate, 325 g/kg calcium hydrogen phosphate, 185
g/kg disodium hydrogen phosphate, 205 g/kg potassium chloride, 4.5 g/kg magnesium
sulfate, 4.35 g/kg ferric citrate, 0.375 g/kg copper sulfate, 0.75 g/kg zinc carbonate, and
0.025 g/kg potassium iodate (commercially prepared by Arthur H. Cox, Brighton, UK).
**Containing 2 g choline chloride, 20 mg calcium pantothenate, 3 mg thiamine, 3 mg
pyridoxine, 3 mg riboflavin, 25 mg nicotinamide, 0.1 mg biotin, and 0.05 mg cyanoco-
balamin. ***Each rat received weekly doses of fat-soluble vitamins in arachis oil
containing 344 µg retinyl acetate, 5 µg ergocalciferol, 2 mg DL-alpha-tocophenylac-
etate, and 0.05 mg 2-methyl-1,4-naphthoquinone.
Constituent (g/kg diet) Control Low-protein
Casein 210 31.5
Cystine 3 0.45
Sucrose 355 444.5
Starch 355 444.5
Corn oil 30 30
Salt mixture* 50 50
Total 1003 1001
B-vitamin and choline chloride mixture (ml/kg)** 10 10
Fat-soluble vitamin mixture*** 1 dose/week 1 dose/week
Energy content (MJ/kg) 16.70 16.70
Carbohydrate (g/kg) 701 879
Protein (g) 209 31
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ad libitum-fed rats (group A) (Table 2). In
addition, treatment with this specific NE
agonist diminished even further plasma al-
bumin levels (group P and group A vs group
CL). The pair-fed group, on the other hand,
showed a small but significant elevation in
plasma albumin, probably due to the slight
decrease in food intake in comparison to A
rats. Plasma T3 levels were significantly
higher when rats were treated with the low-
protein diet (groups A, P and CL vs C). Drug
treatment, on the other hand, did not modify
the plasma T3 levels among the groups fed
the low-protein diet. No changes in plasma
insulin levels were observed between the
four groups (Table 2). The decrease in plasma
albumin levels in rats fed the low-protein
diet (group A) was accompanied by a marked
reduction in liver weight and protein content
(when expressed as mg/total liver) in com-
parison to control rats (Table 3). CL treat-
ment worsened this hepatic depletion (group
A and P vs group CL). No differences were
found in gastrocnemius weight (mg/kg body
Table 2 - Effect of clenbuterol (CL) on food consumption, weight gain and plasma measurements.
Results are reported as means ± SEM for 6 animals per group. Group C: Normally fed control rats; group A:
low-protein with free access to food; group P: pair-fed with group CL; group CL: low-protein diet + Cl for 2
weeks. *Values on the same row not sharing a common superscript are significantly different (ANOVA
followed by Fisher’s least-significant-difference test).
C A P CL
Food consumption 118.9 ± 3.2 129.9 ± 6.3 117.1 ± 9.6 118.3 ± 9.3
(g/day x kg body weight)
Weight gain (g) 91.7 ± 3.8a* 4.8 ± 1.0b 3.2 ± 1.1b -10.2 ± 1.9c
Plasma albumin (g/l) 31.11 ± 0.29a 25.05 ± 0.31b 26.72 ± 0.59c 23.64 ± 0.30d
Plasma T3 (µg/l) 1.15 ± 0.07a 1.56 ± 0.02b 1.39 ± 0.10b 1.47 ± 0.60b
Plasma insulin (mU/l) 16.46 ± 4.53 28.81 ± 4.58 27.82 ± 4.99 38.14 ± 7.57
Table 3 - Effect of clenbuterol (CL) on liver and gastrocnemius weight and protein content.
Results are reported as means ± SEM for 6 animals per group. Group C: Normally fed control rats; group A:
low-protein with free access to food; group P: pair-fed with group CL; group CL: low-protein diet + Cl for 2
weeks. Values on the same row not sharing a common superscript are significantly different (ANOVA
followed by Fisher’s least-significant-difference test).
C A P CL
Liver weight
(g) 10.44 ± 0.46a 4.47 ± 0.29b 4.33 ± 0.42b 2.68 ± 0.26c
(g/kg body weight) 52.02 ± 0.99a 46.62 ± 1.27a 49.13 ± 0.79a 39.02 ± 0.89b
Liver protein
(mg/g liver) 121.32 ± 3.33a 166.37 ± 7.41b 176.41 ± 6.10b 199.25 ± 3.08c
(mg/total liver) 1326.61 ± 108.96a 736.56 ± 26.27b 784.15 ± 64.72b 535.41 ± 53.66c
Gastrocnemius weight
(mg) 944 ± 98a 529 ± 34b 510 ± 54b 410 ± 43b
(mg/kg body weight) 5389 ± 255 5867 ± 85 5767 ± 89 5784 ± 100
Gastrocnemius protein
(mg/g muscle) 210.88 ± 3.20a 211.78 ± 3.05a 218.12 ± 1.41a 227.14 ± 1.67b
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weight) between the four groups (Table 3).
On the other hand, clenbuterol administra-
tion increased gastrocnemius muscle protein
content in comparison to the other groups
(C, A, and P) (Table 3). The drug treatment
also led to an alteration in body composition,
increasing body water and decreasing body
fat content (Table 4). BAT weight and cyto-
chrome oxidase activity, although slightly
lower than in pair-fed rats (group P vs group
CL), was still much higher than control rats
(group C vs group CL) (Table 4).
Discussion
It is clear from the results obtained that
stimulation of the ß-2-adrenergic system with
clenbuterol caused an exacerbation of the
symptoms associated with protein deficiency
in rats. Plasma albumin concentrations, al-
ready low in rats fed the low-protein diet,
were further reduced in the treated animals
(6). In association with this reduction in
plasma albumin, total liver protein decreased
below the level seen in animals with free
access to the low-protein diet, whereas gas-
trocnemius muscle protein was higher than
the well-preserved values normally described
for the animals fed the low-protein diet found
by us and others (15). Moreover, most of
these changes were dose dependent (results
not shown), the effect being more pronounced
as clenbuterol concentration in the diet in-
creased. Clearly, the overall dysadaptation
effect of the low-protein diet was increased
by drug administration.
In spite of the absence of a significant
difference in food intake, clenbuterol-treated
rats showed a much greater reduction in
growth when compared to the respective
pair-fed rats. This was associated with a
marked decrease in fat stores. The negative
effects on growth performance clearly indi-
cate that a substantial augmentation in the
energy metabolism in general had occurred
(not due to elevation of specific BAT ther-
mogenesis), in keeping with results reported
by other authors (9,12). The absence of BAT
thermogenesis elevation in this situation of
clearly low energy efficiency can be ex-
plained since it is known that BAT thermo-
genic activity is stimulated mainly by ß-1
adrenergic receptors although some stimula-
tion of ß-2 receptors does occur (18). When
it is considered that, in these rats fed a low-
protein diet, BAT activity is already substan-
tially increased it is easy to understand why
this less potent stimulus action via ß-2 recep-
Table 4 - Effect of clenbuterol (CL) on brown adipose tissue (BAT) and carcass composition.
Results are reported as means ± SEM for 6 animals per group. Group C: Normally fed control rats; group A:
low-protein with free access to food; group P: pair-fed with group CL; group CL: low-protein diet + Cl for 2
weeks. Values on the same row not sharing a common superscript are significantly different (ANOVA
followed by Fisher’s least-significant-difference test). +U (units) are defined as µmol of reduced cytochrome c
oxidized/min per total interscapular brown adipose tissue.
C A P CL
BAT weight
(mg) 645 ± 53a* 456 ± 12b 490 ± 37b 313 ± 12c
(mg/kg body weight) 3209 ± 213a 5131 ± 312b 5615 ± 249b 4633 ± 255c
BAT cytochrome oxidase
(U/BAT)+ 31.72 ± 1.37a 38.61 ± 1.62b 40.48 ± 2.80b 28.43 ± 2.43c
(U/BAT x kg body weight) 159.6 ± 11.54a 431.8 ± 21.46b,c 469.96 ± 16.20b 414.48 ± 11.32c
Carcass composition
Body water (%) 66.50 ± 0.44a 66.66 ± 0.29a 66.48 ± 0.45a 70.05 ± 0.15b
Body fat (%) 9.16 ± 0.61a 8.93 ± 0.40a 9.18 ± 0.62a 4.24 ± 0.23b
Total body fat (g) 19.28 ± 1.50a 5.28 ± 0.30b 5.35 ± 0.81b 2.02 ± 0.16c
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tors would fail to cause further elevation in
BAT activity. In the present study, BAT
cytochrome oxidase activity was in fact
slightly decreased although not different from
rats with free access to the low-protein diet.
On the other hand, one could argue that
the reduced growth of drug-treated animals
could have arisen from intestinal malabsorp-
tion of the food consumed because it is
known that sympathetic stimulation promotes
intestinal relaxation. If this suggestion is
correct, however, treatment with CL should
have caused metabolic changes such as those
seen in energy-restricted animals i.e., a re-
covery of plasma albumin levels, a decrease
of plasma total T3 values, an improvement of
liver protein, etc. In fact the changes seen in
CL-treated rats were the opposite of what
would have been expected. Therefore it ap-
pears that the most likely explanation for the
decrease in body weight and carcass fat in
low-protein-CL-treated rats is a general in-
crease in metabolic rate stimulated by this ß-
2 selective agonist.
In common with other studies, our results
indicate that clenbuterol increases muscle
protein content associated with a decrease in
liver protein content (expressed per total
liver), and has a powerful lipolytic action
(10-12). These observations suggest that
plasma albumin synthesis was impaired by a
direct ß-2 adrenergic-mediated stimulation
of muscle protein content. Moreover these
findings corroborate the description of the
metabolic dysadaptation seen in protein-de-
ficient rats and support the suggestion that it
is the better muscle preservation that prob-
ably decreases amino acid availability to the
liver and, by reducing albumin synthesis,
causes hypoalbuminemia.
These findings are consistent with the
findings of other studies. Emery et al. (21),
studying protein synthesis in liver, skeletal
muscle and BAT of rats fed a 7.6% protein
diet for 2 weeks, showed that there were
differences in muscle and liver protein syn-
thesis in response to this diet. In addition,
they showed that there was a decrease in
synthesis in both tissues but a preservation
of protein mass in BAT. However, liver and
muscle responded differently to the stress of
protein deficiency. In the liver, the depressed
protein synthesis was due to a fall (20%
lower than control) in the activity of RNA (g
protein synthesized g RNA-1 day-1) with no
change in RNA content. Conversely, in skel-
etal muscle, RNA activity was unaltered by
diet and the depressed protein synthesis could
be entirely ascribed to a fall in RNA content.
Similar findings were also obtained by
Waterlow et al. (22) in animals fed a 3.5%
protein diet.
It is not known why these differences in
liver and muscle occur. In this experimental
protocol no significant differences in plasma
total T3 or insulin were observed. Crowe and
Royle (23) found low insulin and plasma
glucose levels but increased insulin sensitiv-
ity in rats fed a low-protein diet (4% protein)
compared to a pair-fed group receiving a
14.4% protein diet. On the other hand,
Sakuma et al. (2) found evidence that rats fed
the 3% protein diet but with a normal energy
intake presented differences in gene regula-
tion when compared to rats fed a low-protein
low-energy diet. These authors found that
this nutritional condition brought about a
decrease of albumin mRNA concentration
both in total cytoplasmatic RNA and in
poly[A]t RNA to the same extent as that of
serum albumin concentration. Whichever the
mechanisms involved in the regulation of
liver and muscle protein synthesis in this
condition of low-protein intake, the present
results indicate that ß-2 selective adrenergic
stimulation by clenbuterol increased muscle
protein and perhaps as a consequence re-
duced the liver amino acid availability.
In conclusion, the present findings sug-
gest that the mechanisms that deal with
muscle protein preservation in animals fed a
low-protein diet, such as ß-2 sympathetic
activation, may also promote liver impair-
ment and consequently hypoalbuminemia.
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